Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →B grade PMID 42748428
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42765973
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →The study reports that doxorubicin-loaded, poly(2-oxazoline)-coated porous silicon nanoparticles bearing alendronate and an IGF-2 receptor antibody achieved high drug loading, pH-responsive release, increased osteosarcoma-cell association and hydroxyapatite binding, and greater in-vitro cytotoxicity than comparator formulations or free doxorubicin.
The supplied evidence shows enhanced targeting-associated cellular uptake and cytotoxicity in osteosarcoma cell models; it supports the inference—but does not establish—that dual bone- and receptor-targeting could improve tumor-selective doxorubicin delivery and potentially reduce systemic exposure or toxicity in vivo.
In a cross-sectional matched case-control analysis of 265 Wilms tumor survivors, metabolic syndrome was more prevalent than in controls, with abdominal radiotherapy—particularly pancreatic and intra-abdominal fat exposure—associated with metabolic abnormalities and modeled dose-dependent risk.
The record provides observational evidence linking abdominal radiotherapy and estimated organ doses to later metabolic syndrome components; it supports, but does not establish, the hypothesis that pancreas- and abdominal-fat-sparing radiotherapy planning, dose reduction where oncologically feasible, and targeted metabolic surveillance could reduce or mitigate late cardiovascular risk.
In a single-center retrospective cohort of 232 children with ALL treated using the BFM-95 protocol in Kashmir, five-year overall and event-free survival were 74.5% and 66.9%, while MRD positivity, failure to achieve Day 33 marrow remission, MLL rearrangement, and CNS involvement independently predicted inferior survival.
The study provides clinical association evidence that early MRD and marrow response identify children at elevated risk; it is reasonable—but not tested here—to hypothesize that broader access to these assessments and prospectively validated response-adapted treatment could improve treatment selection and outcomes in similar resource-limited settings.
In a 10-year single-institution retrospective series of 11 children with vascular tumors or malformations, sirolimus—usually given as salvage therapy—was associated with 10 partial responses, one stable disease, and reported adverse events in four patients.
The reported clinical responses support the hypothesis that sirolimus may provide disease control for selected pediatric refractory or unresectable vascular anomalies, including rare vascular tumors; however, efficacy, optimal patient selection, and safety require confirmation in larger prospective studies.
In a two-school cluster-randomized study of 524 adolescents aged 13–16 years, a teacher- and peer-delivered social cognitive theory-based module improved oral-cancer knowledge and self-efficacy through three months compared with conventional education.
The reported evidence supports short-term improvement in awareness and self-efficacy; it is reasonable but unproven to hypothesize that broader implementation could reduce oral-cancer risk by promoting durable preventive behavior, because risk-factor behavior, cancer incidence, and clinical outcomes were not measured.
This mini-review summarizes the diagnostic complexity, molecular heterogeneity, and emerging therapeutic approaches for rare ALK-negative anaplastic large cell lymphoma in children, adolescents, and young adults.
The review reports recurrent molecular alterations and identifies CD30-directed therapy, JAK/STAT inhibition, and checkpoint blockade as emerging approaches; it is reasonable to infer that molecularly stratified testing of these strategies could benefit selected young patients, but the supplied record provides no original efficacy or safety results.
In a Dutch cohort of 292 children treated with ifosfamide, 42.1% met the study definition of CKD within five years, with higher cumulative ifosfamide exposure, older age at diagnosis, and at least two acute kidney injury episodes associated with increased risk.
The study provides observational evidence that cumulative ifosfamide dose and recurrent treatment-associated acute kidney injury identify children at elevated early CKD risk; it is reasonable, but not tested here, to hypothesize that dose-aware treatment planning, AKI prevention, and risk-adapted renal surveillance could reduce or detect toxicity earlier.
A modified Delphi panel of 18 pediatric neurology specialists reached consensus on when to initiate and wean anti-seizure medication, preferred first- and second-line agents, selective use of EEG before weaning, and indications for early epilepsy-surgery evaluation in children with brain tumor-associated seizures.
The report directly supports expert-consensus management pathways for pediatric brain tumor-associated epilepsy; it is reasonable—but not demonstrated by this study—to hypothesize that standardized initiation, medication selection, weaning, EEG assessment, and surgical referral could reduce seizure-related morbidity or unnecessary treatment exposure.
This patient-level systematic review of 57 published definite teratoid Wilms tumor cases found substantial histologic heterogeneity, frequently limited neoadjuvant chemotherapy response among evaluable patients, and generally favorable reported survival, with complete resection remaining central to management.
The review provides clinical evidence that neoadjuvant chemotherapy response is often limited in reported teratoid Wilms tumor cases; as an inference requiring prospective validation, recognizing extensive teratoid differentiation could help guide earlier surgical assessment or subtype-specific treatment research rather than reliance on chemotherapy response alone.
This meta-analysis of 13 randomized controlled trials involving 1,022 parents found that eHealth interventions reduced parental depression, while evidence for anxiety, quality of life, and post-traumatic stress symptoms was uncertain or unstable.
Evidence from the pooled trials supports eHealth interventions as a potentially useful supportive-care approach for reducing depression in parents of children with cancer; it is inferential, rather than demonstrated here, that improving caregiver mental health could benefit family functioning or pediatric cancer outcomes.
In a multicentre retrospective cohort of 110 patients aged 15–25 years with prolactinomas, cabergoline commonly normalized prolactin and reduced tumour size, but partial resistance and recurrence after treatment withdrawal were frequent, with younger diagnostic age and shorter treatment duration associated with recurrence.
The study provides observational evidence that longer cabergoline treatment before withdrawal is associated with less recurrence, including a derived 45.5-month threshold; it is reasonable—but not proven—to hypothesize that prospectively validated, duration-informed withdrawal criteria could reduce recurrence in transition-age patients without unnecessarily prolonging therapy.
In a prospective Scottish cohort of 190 symptomatic cerebral cavernous malformation patients followed for a median of 16 years, intervention was associated with some measures of functional dependence or death and CCM- or intervention-related hemorrhage/focal neurologic deficit, but not with seizures.
The evidence suggests that microsurgery or stereotactic radiosurgery may not improve—and may worsen selected long-term outcomes compared with conservative management in symptomatic CCM; whether careful treatment selection or conservative management improves outcomes is an inference requiring a randomized trial.
